Agios Pharmaceuticals Inc (NASDAQ:AGIO)

77.53
Delayed Data
As of 4:00pm ET
 -0.17 / -0.22%
Today’s Change
45.11
Today|||52-Week Range
82.96
+35.61%
Year-to-Date
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Feb 16 / Zacks.com - Paid Partner Content
Agios (AGIO) Q4 Loss Wider than Expected; Sales Miss
Feb 14 / Zacks.com - Paid Partner Content
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
Feb 15 / Zacks.com - Paid Partner Content
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
Feb 09 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close77.70
Today’s open76.96
Day’s range76.25 - 79.96
Volume405,575
Average volume (3 months)524,902
Market cap$4.5B
Data as of 4:00pm ET, 02/20/2018

Growth & Valuation

Earnings growth (last year)-33.14%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)-38.46%
P/E ratioNM
Price/Sales61.92
Price/Book10.10

Competitors

 Today’s
change
Today’s
% change
HCMHutchison China Medi...+0.76+2.25%
SAGESAGE Therapeutics In...+0.81+0.50%
ICPTIntercept Pharmaceut...-0.38-0.62%
LGNDLigand Pharmaceutica...-1.63-1.04%
Data as of 4:00pm ET, 02/20/2018

Financials

Last reporting dateFebruary 14, 2018
EPS forecast (this quarter)-$1.62
Annual revenue (last year)$43.0M
Annual profit (last year)-$314.7M
Net profit margin-731.60%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
David Paul Schenkein
Chief Financial Officer
Andrew J. Hirsch
Corporate headquarters
Cambridge, Massachusetts

Forecasts